Zydus Cadila says 'positive results' from phase 2 studies of COVID-19 drug Desidustat in Mexico

Drug firm Zydus Cadila on Monday said it has received positive results from phase 2b studies of Desidustat in COVID-19 patients conducted in Mexico. None of the hospitalised patients required mechanical ventilator in the Desidustat arm, while 25 per cent of COVID-19 patients on the standard of care arm required mechanical ventilation. Pankaj R Patel, Chairman, Zydus Group said, We are excited to report for the first time, this encouraging data of...

PTI | New Delhi | Updated: 25-01-2021 10:52 IST | Created: 25-01-2021 10:49 IST
Zydus Cadila says 'positive results' from phase 2 studies of COVID-19 drug Desidustat in Mexico
Representative image Image Credit: ANI

Drug firm Zydus Cadila on Monday said it has received positive results from phase 2(b) studies of Desidustat in COVID-19 patients conducted in Mexico. In June 2020, Zydus Cadila had received approval from Mexico's regulatory authority Cofepris to test one of its lead research candidate Desidustat in the management of COVID-19.

The company has received positive results from phase 2(b) studies of Desidustat in COVID-19 patients, Cadila Healthcare said in a regulatory filing.

Zydus Cadila, which is part of Cadila Healthcare, said: ''Patients infected with COVID-19 have been reported to display signs of 'Hypoxia' leading to organ failure and death despite the use of antivirals, anti-inflammatory drugs or ventilators... The phase 2(b) results of this study revealed that Desidustat treatment led to increased red blood cell production and improved oxygen delivery to tissues. ''None of the hospitalised patients required mechanical ventilator in the Desidustat arm, while 25 per cent of COVID-19 patients on the standard of care arm required mechanical ventilation.'' Pankaj R Patel, Chairman, Zydus Group said, "We are excited to report for the first time, this encouraging data of... Desidustat, showing the potential to help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients. ARDS is associated with high mortality rate and Zydus remains committed to further develop this novel therapy for patients suffering from ARDS.'' Clinical and regulatory development of Desidustat in COVID-19 was executed in Mexico by Avant Santé Research Center S.A. de C.V., a leading Contract Research Organization (CRO) headquartered in Monterrey, Mexico, the company said. Shares of Cadila Healthcare were trading 0.59 per cent higher at Rs 463 apiece on the BSE.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)


TRENDING

OPINION / BLOG / INTERVIEW

Why unequal access to coronavirus vaccines is a threat to us all

... ...

India’s love affair with fossil fuels: the path to sustainable development?

... ...

Videos

Latest News

Moderna is developing booster shot for new coronavirus variants, increases vaccine production target

Moderna Inc said on Wednesday it is working with U.S. government scientists to study an experimental booster shot that targets a concerning new variant of the coronavirus and has raised its global COVID-19 vaccine production goal for this y...

UN: Yemen faces world's worst famine and needs $3.85 billion

Conflict-torn Yemen is falling off a cliff and will face the worst famine the world has seen for decades unless donors, and especially its Gulf neighbours, contribute generously to this years UN humanitarian appeal for 3.85 billion, the UN ...

Frontline workers, BAME groups will not be prioritised for UK vaccines -Guardian

Frontline workers and Black, Asian and minority ethnic groups BAME in the United Kingdom will not be prioritised for COVID-19 vaccination in the next stage of the vaccine rollout, the Guardian reported on Wednesday.The Joint Committee on Va...

Northern Ireland's first minister ups ante in UK-EU trade dispute

Northern Irelands first minister upped the ante on Wednesday in a dispute between the UK and the European Union over trade with the province, calling on Prime Minister Boris Johnson to step up and protect the United Kingdom.Earlier the UK a...

Give Feedback